出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2023年12月
Tissue Engineering Market – Global Forecast to 2028
組織工学市場 : 製品 [足場 (コラーゲン、幹細胞)、組織移植片 (同種移植片、自家移植片、異種移植片)]、材料 (生物学的、合成)、用途 (整形外科、皮膚科、創傷治療、心臓血管) – 2028年までの世界予測
Tissue Engineering Market by Product (Scaffolds (Collagen, Stem Cell), Tissue Grafts (Allograft, Autograft, Xenograft)), Material (Biological, Synthetic), Application (Orthopedics, Dermatology, Wound Care, Cardiovascular) – Global Forecast to 2028
| ページ数 | 344 |
| 図表数 | 413 |
| 種別 | 英文調査報告書 |
| 価格 |
Report Overview
The tissue engineering market is projected to reach USD 8.9 billion by 2028 from an estimated USD 4.4 billion in 2023, at a CAGR of 15.3% during the forecast period. The growth of this market can be attributed to rising funding and investments for the development of advanced tissue engineering solutions and growing technological advancements in regenerative medicines. In addition, increasing incidences of road accidents and trauma injuries drive the demand for tissue engineering products. The rising demand for tissue-engineered products for the treatment of chronic and degenerative diseases is promoting the growth of the market.
“The synthetic material segment accounted for the largest share by material in 2022.”
The synthetic material segment accounted for the largest share of material in the global tissue engineering market in 2022. Various factors, such as increasing demand for innovative tissue engineering solutions for tissue repair and regeneration and growing investments and government funding for the advancement of technologies in the healthcare sector, are driving the demand for synthetic materials in the tissue engineering market. Additionally, the market share of the synthetic material market is expected to grow simultaneously with the growing demand for regenerative medicines.
“The Asia Pacific region is growing in the tissue engineering market during the forecast period of 2023-2028.”
Increasing R&D activities and the growing adoption of advanced medical care technologies are the major factors driving the adoption of tissue engineering. The Asia Pacific region is growing at a higher rate during the forecast period. Several factors, including the growing adoption of advanced medical care technologies and the booming healthcare industry, are propelling the growth of the tissue engineering market in the region. The increasing advancements in cell therapies and regenerative medicines are promoting the growth of the tissue engineering market in the region. For instance, the Department of Science & Technology (DST), Government of India, Inspire fellows are developing biomaterials for bone tissue regeneration. The study focuses on the development of materials for therapeutic applications and studying properties of stem cells for tissue regeneration.
The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 80% and Demand Side 20%
• By Designation: Managers – 45%, CXO & Directors – 30%, and Executives – 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10% and Middle East & Africa- 5%
List of Companies Profiled in the Report:
• Organogenesis (US)
• AbbVie Inc. (US)
• Baxter (US)
• BD (US)
• B. Braun (Germany)
• TEIJIN Limited (Japan)
• Institut Straumann AG (Switzerland)
• Integra Lifesciences (US)
• Johnson & Johnson Services, Inc. (US)
• Medtronic (Ireland)
• NuVasive, Inc. (US)
• Stryker (US)
• Terumo Corporation (Japan)
• W. L. Gore & Associates Inc. (US)
• Zimmer Biomet (US)
• Smith & Nephew plc (UK)
• MIMEDX Group, Inc. (US)
• BioTissue (US)
• CollPlant Biotechnologies Ltd. (Israel)
• Sumitomo Pharma Co., Ltd. (Japan)
• Matricel GmbH (Germany)
• Mallinckrodt (US)
• Regrow Biosciences Pvt Ltd (India)
• Vericel Corporation (US)
• Tecnoss S.R.L. (Italy)
• Tegoscience (South Korea)
• Tissue Regenix (UK)
Research Coverage:
This research report categorizes the tissue engineering market by product type (scaffold, tissue grafts, and other products), material (synthetic material and biologically derived material), application (orthopedics & musculoskeletal disorders, dermatology & wound care, dental disorders, cardiovascular diseases, and others), end user (hospitals, specialty centers and clinics, and ambulatory surgical centers)
The report’s scope encompasses detailed information regarding major influencing factors such as drivers, trends, challenges, and opportunities shaping the growth of the tissue engineering market. A comprehensive analysis of key industry players has been conducted to offer insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. The report also covers recent developments, including new product launches, mergers and acquisitions, and the tissue engineering market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall tissue engineering market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (rising funding and investments for the development of innovative tissue engineering products and growing need for tissue engineering solutions), restraints (strict regulations), opportunities (increasing technological advancements such as 3D bioprinting and organ-on-chip technology), and challenges (limited awareness for tissue engineering) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products of the tissue engineering market
• Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the tissue engineering market
• Competitive Assessment: Organogenesis (US), AbbVie Inc. (US), Baxter (US), BD (US), B. Braun (Germany), TEIJIN Limited (Japan), Institut Straumann AG (Switzerland), Integra Lifesciences (US), Johnson & Johnson Services, Inc. (US), Medtronic (Ireland), NuVasive, Inc. (US), Stryker (US), Terumo Corporation (Japan), W. L. Gore & Associates Inc. (US), Zimmer Biomet (US), Smith & Nephew plc (UK), MIMEDX Group, Inc. (US), BioTissue (US), CollPlant Biotechnologies Ltd. (Israel), Sumitomo Pharma Co., Ltd. (Japan), Matricel GmbH (Germany), Mallinckrodt (US), Regrow Biosciences Pvt Ltd (India), Vericel Corporation (US), Tecnoss S.R.L. (Italy), Tegoscience (South Korea), and Tissue Regenix (UK).
Table of Contents
1 INTRODUCTION 45
1.1 STUDY OBJECTIVES 45
1.2 MARKET DEFINITION & SCOPE 45
1.2.1 INCLUSIONS AND EXCLUSIONS 46
1.2.2 MARKETS COVERED 47
1.2.3 YEARS CONSIDERED 48
1.3 CURRENCY 48
1.4 STAKEHOLDERS 48
1.5 LIMITATIONS 49
1.6 RECESSION IMPACT 49
2 RESEARCH METHODOLOGY 50
2.1 RESEARCH DATA 50
FIGURE 1 RESEARCH DESIGN 50
2.1.1 SECONDARY DATA 51
2.1.2 PRIMARY DATA 52
FIGURE 2 TISSUE ENGINEERING MARKET: BREAKDOWN OF PRIMARIES 52
2.2 MARKET SIZE ESTIMATION 53
FIGURE 3 TISSUE ENGINEERING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022 53
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022 54
FIGURE 5 ILLUSTRATIVE EXAMPLE OF ABBVIE INC.: REVENUE SHARE ANALYSIS, 2022 54
2.2.1 INSIGHTS FROM PRIMARIES 56
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS 56
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 56
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 57
FIGURE 8 TISSUE ENGINEERING MARKET: CAGR PROJECTIONS 58
FIGURE 9 TISSUE ENGINEERING MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 58
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 59
FIGURE 10 DATA TRIANGULATION METHODOLOGY 59
2.5 RESEARCH ASSUMPTIONS 60
2.6 RISK ANALYSIS 60
2.7 RECESSION IMPACT ANALYSIS 61
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH) 61
TABLE 2 US: HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 61
TABLE 3 US: HEALTH EXPENDITURE, 2023–2030 (USD MILLION) 61
3 EXECUTIVE SUMMARY 62
FIGURE 11 TISSUE ENGINEERING MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 62
FIGURE 12 TISSUE ENGINEERING MARKET, BY MATERIAL, 2023 VS. 2028 (USD MILLION) 63
FIGURE 13 TISSUE ENGINEERING MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 63
FIGURE 14 TISSUE ENGINEERING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 64
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF TISSUE ENGINEERING MARKET 65
4 PREMIUM INSIGHTS 66
4.1 TISSUE ENGINEERING MARKET OVERVIEW 66
FIGURE 16 GROWING DEMAND FOR REGENERATIVE MEDICINE TO DRIVE MARKET 66
4.2 ASIA PACIFIC: TISSUE ENGINEERING MARKET, BY MATERIAL AND COUNTRY (2022) 67
FIGURE 17 SYNTHETIC MATERIALS HELD LARGEST SHARE OF ASIA PACIFIC TISSUE ENGINEERING MARKET IN 2022 67
4.3 TISSUE ENGINEERING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 68
FIGURE 18 INDIA TO WITNESS HIGHEST GROWTH IN TISSUE ENGINEERING MARKET DURING FORECAST PERIOD 68
4.4 TISSUE ENGINEERING MARKET SHARE, BY PRODUCT, 2022 68
FIGURE 19 SCAFFOLDS ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 68
5 MARKET OVERVIEW 69
5.1 INTRODUCTION 69
5.2 MARKET DYNAMICS 69
FIGURE 20 TISSUE ENGINEERING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 69
TABLE 4 TISSUE ENGINEERING MARKET: IMPACT ANALYSIS 70
5.2.1 DRIVERS 70
5.2.1.1 Growing demand for regenerative medicine 70
5.2.1.2 Ongoing clinical trials and approvals in tissue engineering field 71
TABLE 5 ONGOING TISSUE ENGINEERING PRODUCT TRIALS REGISTERED ON CLINICALTRIALS.GOV 71
TABLE 6 EUROPE: TISSUE ENGINEERING PRODUCT TRIALS, JANUARY 2009–DECEMBER 2021 72
5.2.1.3 Availability of funding and investments for research and development of tissue engineering products 73
5.2.2 RESTRAINTS 74
5.2.2.1 High treatment cost 74
5.2.2.2 Complex regulatory process 74
5.2.3 OPPORTUNITIES 75
5.2.3.1 Emerging economies 75
5.2.3.2 Technological advancements in tissue engineering products 75
5.2.4 CHALLENGES 76
5.2.4.1 Cost-effective traditional organ transplant technique 76
5.2.4.2 Limited awareness 76
5.2.4.3 Safety concerns and complexity of biomaterials 77
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 77
FIGURE 21 REVENUE SHIFT AND NEW POCKETS FOR TISSUE ENGINEERING PRODUCT PROVIDERS 77
5.4 PRICING ANALYSIS 78
TABLE 7 AVERAGE PRICE OF TISSUE ENGINEERING PRODUCTS, BY COMPANY, 2022 78
TABLE 8 AVERAGE PRICE OF TISSUE ENGINEERING PRODUCTS, BY REGION, 2022 79
5.5 VALUE CHAIN ANALYSIS 79
FIGURE 22 VALUE CHAIN ANALYSIS OF TISSUE ENGINEERING MARKET: R&D AND MANUFACTURING PHASES ADD MAXIMUM VALUE 79
5.6 SUPPLY CHAIN ANALYSIS 81
FIGURE 23 TISSUE ENGINEERING MARKET: SUPPLY CHAIN ANALYSIS 82
5.7 ECOSYSTEM ANALYSIS 82
TABLE 9 ECOSYSTEM FOR TISSUE ENGINEERING 82
5.8 TECHNOLOGY ANALYSIS 83
5.9 PATENT ANALYSIS 84
FIGURE 24 PATENT APPLICATIONS FOR TISSUE ENGINEERING MARKET, JANUARY 2013–OCTOBER 2023 84
TABLE 10 INDICATIVE LIST OF PATENTS IN TISSUE ENGINEERING MARKET 85
5.10 KEY CONFERENCES AND EVENTS IN 2023–2024 86
TABLE 11 TISSUE ENGINEERING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS 86
5.11 REGULATORY ANALYSIS 87
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 15 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89
5.12 PORTER’S FIVE FORCES ANALYSIS 89
TABLE 16 TISSUE ENGINEERING MARKET: PORTER’S FIVE FORCES ANALYSIS 89
5.12.1 THREAT OF NEW ENTRANTS 90
5.12.2 THREAT OF SUBSTITUTES 90
5.12.3 BARGAINING POWER OF SUPPLIERS 90
5.12.4 BARGAINING POWER OF BUYERS 90
5.12.5 INTENSITY OF COMPETITIVE RIVALRY 91
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 91
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 91
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TISSUE ENGINEERING PRODUCTS 91
5.13.2 BUYING CRITERIA FOR TISSUE ENGINEERING PRODUCTS 92
FIGURE 26 KEY BUYING CRITERIA FOR END USERS 92
6 TISSUE ENGINEERING MARKET, BY PRODUCT 94
6.1 INTRODUCTION 95
TABLE 17 TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 95
6.2 SCAFFOLDS 95
TABLE 18 SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 96
TABLE 19 SCAFFOLDS MARKET, BY REGION, 2021–2028 (USD MILLION) 96
TABLE 20 NORTH AMERICA: SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 21 EUROPE: SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 22 ASIA PACIFIC: SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 23 LATIN AMERICA: SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 24 MIDDLE EAST & AFRICA: SCAFFOLDS MARKET, BY REGION, 2021–2028 (USD MILLION) 98
6.2.1 SYNTHETIC SCAFFOLDS 99
6.2.1.1 Controlled degradation rate and ability to design specific microarchitecture to drive adoption 99
TABLE 25 SYNTHETIC SCAFFOLDS MARKET, BY REGION, 2021–2028 (USD MILLION) 99
TABLE 26 NORTH AMERICA: SYNTHETIC SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 27 EUROPE: SYNTHETIC SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 28 ASIA PACIFIC: SYNTHETIC SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 29 LATIN AMERICA: SYNTHETIC SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 30 MIDDLE EAST & AFRICA: SYNTHETIC SCAFFOLDS MARKET, BY REGION, 2021–2028 (USD MILLION) 101
6.2.2 BIOLOGICAL SCAFFOLDS 101
TABLE 31 BIOLOGICAL SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 102
TABLE 32 BIOLOGICAL SCAFFOLDS MARKET, BY REGION, 2021–2028 (USD MILLION) 102
TABLE 33 NORTH AMERICA: BIOLOGICAL SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 34 EUROPE: BIOLOGICAL SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 35 ASIA PACIFIC: BIOLOGICAL SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 36 LATIN AMERICA: BIOLOGICAL SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 37 MIDDLE EAST & AFRICA: BIOLOGICAL SCAFFOLDS MARKET, BY REGION, 2021–2028 (USD MILLION) 105
6.2.2.1 Collagen-based scaffolds 105
6.2.2.1.1 Rising demand for advanced tissue regeneration solutions to drive market 105
TABLE 38 COLLAGEN-BASED SCAFFOLDS MARKET, BY REGION, 2021–2028 (USD MILLION) 106
TABLE 39 NORTH AMERICA: COLLAGEN-BASED SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 40 EUROPE: COLLAGEN-BASED SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 41 ASIA PACIFIC: COLLAGEN-BASED SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 42 LATIN AMERICA: COLLAGEN-BASED SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 43 MIDDLE EAST & AFRICA: COLLAGEN-BASED SCAFFOLDS MARKET, BY REGION, 2021–2028 (USD MILLION) 108
6.2.2.2 Hydrogel-based scaffolds 108
6.2.2.2.1 Low mechanical strength of hydrogels to hamper adoption 108
TABLE 44 HYDROGEL-BASED SCAFFOLDS MARKET, BY REGION, 2021–2028 (USD MILLION) 109
TABLE 45 NORTH AMERICA: HYDROGEL-BASED SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 46 EUROPE: HYDROGEL-BASED SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 47 ASIA PACIFIC: HYDROGEL-BASED SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 48 LATIN AMERICA: HYDROGEL-BASED SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 49 MIDDLE EAST & AFRICA: HYDROGEL-BASED SCAFFOLDS MARKET, BY REGION, 2021–2028 (USD MILLION) 111
6.2.2.3 Stem cell-based scaffolds 111
6.2.2.3.1 Growing adoption of stem cell-based scaffolds for wound healing to drive market 111
TABLE 50 STEM CELL-BASED SCAFFOLDS MARKET, BY REGION, 2021–2028 (USD MILLION) 112
TABLE 51 NORTH AMERICA: STEM CELL-BASED SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 52 EUROPE: STEM CELL-BASED SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 113
TABLE 53 ASIA PACIFIC: STEM CELL-BASED SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 113
TABLE 54 LATIN AMERICA: STEM CELL-BASED SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 55 MIDDLE EAST & AFRICA: STEM CELL-BASED SCAFFOLDS MARKET, BY REGION, 2021–2028 (USD MILLION) 114
6.2.2.4 Other biological material-based scaffolds 114
TABLE 56 OTHER BIOLOGICAL MATERIAL-BASED SCAFFOLDS MARKET, BY REGION, 2021–2028 (USD MILLION) 115
TABLE 57 NORTH AMERICA: OTHER BIOLOGICAL MATERIAL-BASED SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 58 EUROPE: OTHER BIOLOGICAL MATERIAL-BASED SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 59 ASIA PACIFIC: OTHER BIOLOGICAL MATERIAL-BASED SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 60 LATIN AMERICA: OTHER BIOLOGICAL MATERIAL-BASED SCAFFOLDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 61 MIDDLE EAST & AFRICA: OTHER BIOLOGICAL MATERIAL-BASED SCAFFOLDS MARKET, BY REGION, 2021–2028 (USD MILLION) 117
6.3 TISSUE GRAFTS 117
TABLE 62 TISSUE GRAFTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 118
TABLE 63 TISSUE GRAFTS MARKET, BY REGION, 2021–2028 (USD MILLION) 118
TABLE 64 NORTH AMERICA: TISSUE GRAFTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 65 EUROPE: TISSUE GRAFTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 66 ASIA PACIFIC: TISSUE GRAFTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 67 LATIN AMERICA: TISSUE GRAFTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 68 MIDDLE EAST & AFRICA: TISSUE GRAFTS MARKET, BY REGION, 2021–2028 (USD MILLION) 120
6.3.1 ALLOGRAFTS 120
6.3.1.1 Risk of donor-to-recipient disease transmission to restrict market growth 120
TABLE 69 ALLOGRAFTS MARKET, BY REGION, 2021–2028 (USD MILLION) 121
TABLE 70 NORTH AMERICA: ALLOGRAFTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 71 EUROPE: ALLOGRAFTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 72 ASIA PACIFIC: ALLOGRAFTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 73 LATIN AMERICA: ALLOGRAFTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 123
TABLE 74 MIDDLE EAST & AFRICA: ALLOGRAFTS MARKET, BY REGION, 2021–2028 (USD MILLION) 123
6.3.2 AUTOGRAFTS 123
6.3.2.1 Advancements in tissue processing techniques to support market growth 123
TABLE 75 AUTOGRAFTS MARKET, BY REGION, 2021–2028 (USD MILLION) 124
TABLE 76 NORTH AMERICA: AUTOGRAFTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 77 EUROPE: AUTOGRAFTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 78 ASIA PACIFIC: AUTOGRAFTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 79 LATIN AMERICA: AUTOGRAFTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 80 MIDDLE EAST & AFRICA: AUTOGRAFTS MARKET, BY REGION, 2021–2028 (USD MILLION) 126
6.3.3 SYNTHETIC GRAFTS 126
6.3.3.1 Continuous innovations in materials science and engineering to drive market 126
TABLE 81 SYNTHETIC GRAFTS MARKET, BY REGION, 2021–2028 (USD MILLION) 127
TABLE 82 NORTH AMERICA: SYNTHETIC GRAFTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 83 EUROPE: SYNTHETIC GRAFTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 84 ASIA PACIFIC: SYNTHETIC GRAFTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 85 LATIN AMERICA: SYNTHETIC GRAFTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 86 MIDDLE EAST & AFRICA: SYNTHETIC GRAFTS MARKET, BY REGION, 2021–2028 (USD MILLION) 128
6.3.4 XENOGRAFTS 129
6.3.4.1 Growing R&D activities to propel market 129
TABLE 87 XENOGRAFTS MARKET, BY REGION, 2021–2028 (USD MILLION) 129
TABLE 88 NORTH AMERICA: XENOGRAFTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 89 EUROPE: XENOGRAFTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 90 ASIA PACIFIC: XENOGRAFTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 91 LATIN AMERICA: XENOGRAFTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 92 MIDDLE EAST & AFRICA: XENOGRAFTS MARKET, BY REGION, 2021–2028 (USD MILLION) 131
6.4 OTHER PRODUCTS 131
TABLE 93 OTHER TISSUE ENGINEERING PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION) 132
TABLE 94 NORTH AMERICA: OTHER TISSUE ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 95 EUROPE: OTHER TISSUE ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 96 ASIA PACIFIC: OTHER TISSUE ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 97 LATIN AMERICA: OTHER TISSUE ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 98 MIDDLE EAST & AFRICA: OTHER TISSUE ENGINEERING PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION) 134
7 TISSUE ENGINEERING MARKET, BY MATERIAL 135
7.1 INTRODUCTION 136
TABLE 99 TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2028 (USD MILLION) 136
7.2 SYNTHETIC MATERIALS 136
7.2.1 ADVANCEMENTS IN SCAFFOLD PREPARATION TECHNIQUES TO SUPPORT MARKET GROWTH 136
TABLE 100 TISSUE ENGINEERING MARKET FOR SYNTHETIC MATERIALS, BY REGION, 2021–2028 (USD MILLION) 137
TABLE 101 NORTH AMERICA: TISSUE ENGINEERING MARKET FOR SYNTHETIC MATERIALS, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 102 EUROPE: TISSUE ENGINEERING MARKET FOR SYNTHETIC MATERIALS, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 103 ASIA PACIFIC: TISSUE ENGINEERING MARKET FOR SYNTHETIC MATERIALS, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 104 LATIN AMERICA: TISSUE ENGINEERING MARKET FOR SYNTHETIC MATERIALS, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 105 MIDDLE EAST & AFRICA: TISSUE ENGINEERING MARKET FOR SYNTHETIC MATERIALS, BY REGION, 2021–2028 (USD MILLION) 139
7.3 BIOLOGICALLY DERIVED MATERIALS 140
7.3.1 INCREASING DEMAND FOR NATURAL MATERIALS TO DRIVE MARKET 140
TABLE 106 TISSUE ENGINEERING MARKET FOR BIOLOGICALLY DERIVED MATERIALS, BY REGION, 2021–2028 (USD MILLION) 140
TABLE 107 NORTH AMERICA: TISSUE ENGINEERING MARKET FOR BIOLOGICALLY DERIVED MATERIALS, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 108 EUROPE: TISSUE ENGINEERING MARKET FOR BIOLOGICALLY DERIVED MATERIALS, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 109 ASIA PACIFIC: TISSUE ENGINEERING MARKET FOR BIOLOGICALLY DERIVED MATERIALS, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 110 LATIN AMERICA: TISSUE ENGINEERING MARKET FOR BIOLOGICALLY DERIVED MATERIALS, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 111 MIDDLE EAST & AFRICA: TISSUE ENGINEERING MARKET FOR BIOLOGICALLY DERIVED MATERIALS, BY REGION, 2021–2028 (USD MILLION) 143
8 TISSUE ENGINEERING MARKET, BY APPLICATION 144
8.1 INTRODUCTION 145
TABLE 112 TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 145
8.2 ORTHOPEDIC & MUSCULOSKELETAL DISORDERS 145
8.2.1 INCREASING INCIDENCE OF ORTHOPEDIC AND MUSCULOSKELETAL DISORDERS TO DRIVE MARKET 145
TABLE 113 TISSUE ENGINEERING MARKET FOR ORTHOPEDIC & MUSCULOSKELETAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 146
TABLE 114 NORTH AMERICA: TISSUE ENGINEERING MARKET FOR ORTHOPEDIC & MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 115 EUROPE: TISSUE ENGINEERING MARKET FOR ORTHOPEDIC & MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 116 ASIA PACIFIC: TISSUE ENGINEERING MARKET FOR ORTHOPEDIC & MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 117 LATIN AMERICA: TISSUE ENGINEERING MARKET FOR ORTHOPEDIC & MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 148
TABLE 118 MIDDLE EAST & AFRICA: TISSUE ENGINEERING MARKET FOR ORTHOPEDIC & MUSCULOSKELETAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 148
8.3 DERMATOLOGY & WOUND CARE 149
8.3.1 GROWING NUMBER OF ROAD ACCIDENTS TO AID MARKET GROWTH 149
TABLE 119 TISSUE ENGINEERING MARKET FOR DERMATOLOGY & WOUND CARE, BY REGION, 2021–2028 (USD MILLION) 149
TABLE 120 NORTH AMERICA: TISSUE ENGINEERING MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION) 150
TABLE 121 EUROPE: TISSUE ENGINEERING MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION) 150
TABLE 122 ASIA PACIFIC: TISSUE ENGINEERING MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 123 LATIN AMERICA: TISSUE ENGINEERING MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 124 MIDDLE EAST & AFRICA: TISSUE ENGINEERING MARKET FOR DERMATOLOGY & WOUND CARE, BY REGION, 2021–2028 (USD MILLION) 152
8.4 DENTAL DISORDERS 152
8.4.1 INCREASING PREVALENCE OF DENTAL DISORDERS TO PROPEL MARKET 152
TABLE 125 TISSUE ENGINEERING MARKET FOR DENTAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 153
TABLE 126 NORTH AMERICA: TISSUE ENGINEERING MARKET FOR DENTAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 127 EUROPE: TISSUE ENGINEERING MARKET FOR DENTAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 154
TABLE 128 ASIA PACIFIC: TISSUE ENGINEERING MARKET FOR DENTAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 154
TABLE 129 LATIN AMERICA: TISSUE ENGINEERING MARKET FOR DENTAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 155
TABLE 130 MIDDLE EAST & AFRICA: TISSUE ENGINEERING MARKET FOR DENTAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 155
8.5 CARDIOVASCULAR DISEASES 155
8.5.1 RISING PREVALENCE OF CARDIOVASCULAR DISEASES TO DRIVE MARKET 155
TABLE 131 TISSUE ENGINEERING MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION) 156
TABLE 132 NORTH AMERICA: TISSUE ENGINEERING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 133 EUROPE: TISSUE ENGINEERING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 157
TABLE 134 ASIA PACIFIC: TISSUE ENGINEERING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 157
TABLE 135 LATIN AMERICA: TISSUE ENGINEERING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 158
TABLE 136 MIDDLE EAST & AFRICA: TISSUE ENGINEERING MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION) 158
8.6 OTHER APPLICATIONS 158
TABLE 137 TISSUE ENGINEERING MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 159
TABLE 138 NORTH AMERICA: TISSUE ENGINEERING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 159
TABLE 139 EUROPE: TISSUE ENGINEERING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 160
TABLE 140 ASIA PACIFIC: TISSUE ENGINEERING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 160
TABLE 141 LATIN AMERICA: TISSUE ENGINEERING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 142 MIDDLE EAST & AFRICA: TISSUE ENGINEERING MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 161
9 TISSUE ENGINEERING MARKET, BY END USER 162
9.1 INTRODUCTION 163
TABLE 143 TISSUE ENGINEERING MARKET, BY END USER, 2021–2028 (USD MILLION) 163
9.2 HOSPITALS 163
9.2.1 RISING ADOPTION OF REGENERATIVE MEDICINE IN DEVELOPING COUNTRIES TO DRIVE MARKET 163
TABLE 144 TISSUE ENGINEERING MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION) 164
TABLE 145 NORTH AMERICA: TISSUE ENGINEERING MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 146 EUROPE: TISSUE ENGINEERING MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION) 165
TABLE 147 ASIA PACIFIC: TISSUE ENGINEERING MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION) 165
TABLE 148 LATIN AMERICA: TISSUE ENGINEERING MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION) 166
TABLE 149 MIDDLE EAST & AFRICA: TISSUE ENGINEERING MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION) 166
9.3 SPECIALTY CENTERS & CLINICS 166
9.3.1 GOVERNMENT SUPPORT AND INITIATIVES TO PROPEL MARKET 166
TABLE 150 TISSUE ENGINEERING MARKET FOR SPECIALTY CENTERS & CLINICS, BY REGION, 2021–2028 (USD MILLION) 167
TABLE 151 NORTH AMERICA: TISSUE ENGINEERING MARKET FOR SPECIALTY CENTERS & CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 167
TABLE 152 EUROPE: TISSUE ENGINEERING MARKET FOR SPECIALTY CENTERS & CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 168
TABLE 153 ASIA PACIFIC: TISSUE ENGINEERING MARKET FOR SPECIALTY CENTERS & CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 168
TABLE 154 LATIN AMERICA: TISSUE ENGINEERING MARKET FOR SPECIALTY CENTERS & CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 169
TABLE 155 MIDDLE EAST & AFRICA: TISSUE ENGINEERING MARKET FOR SPECIALTY CENTERS & CLINICS, BY REGION, 2021–2028 (USD MILLION) 169
9.4 AMBULATORY SURGERY CENTERS 170
9.4.1 GROWING DEMAND FOR CONVENIENT AND HIGH-QUALITY CARE TO SUPPORT MARKET GROWTH 170
TABLE 156 TISSUE ENGINEERING MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2021–2028 (USD MILLION) 170
TABLE 157 NORTH AMERICA: TISSUE ENGINEERING MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2021–2028 (USD MILLION) 171
TABLE 158 EUROPE: TISSUE ENGINEERING MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2021–2028 (USD MILLION) 171
TABLE 159 ASIA PACIFIC: TISSUE ENGINEERING MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2021–2028 (USD MILLION) 172
TABLE 160 LATIN AMERICA: TISSUE ENGINEERING MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2021–2028 (USD MILLION) 172
TABLE 161 MIDDLE EAST & AFRICA: TISSUE ENGINEERING MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2021–2028 (USD MILLION) 173
10 TISSUE ENGINEERING MARKET, BY REGION 174
10.1 INTRODUCTION 175
TABLE 162 TISSUE ENGINEERING MARKET, BY REGION, 2021–2028 (USD MILLION) 175
10.2 NORTH AMERICA 175
FIGURE 27 NORTH AMERICA: TISSUE ENGINEERING MARKET SNAPSHOT 176
TABLE 163 NORTH AMERICA: TISSUE ENGINEERING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 177
TABLE 164 NORTH AMERICA: TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 177
TABLE 165 NORTH AMERICA: TISSUE ENGINEERING SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 177
TABLE 166 NORTH AMERICA: BIOLOGICAL SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 178
TABLE 167 NORTH AMERICA: TISSUE ENGINEERING GRAFTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 178
TABLE 168 NORTH AMERICA: TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2028 (USD MILLION) 179
TABLE 169 NORTH AMERICA: TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 179
TABLE 170 NORTH AMERICA: TISSUE ENGINEERING MARKET, BY END USER, 2021–2028 (USD MILLION) 180
10.2.1 US 180
10.2.1.1 Increasing focus on research in biopharmaceutical field to support market growth 180
TABLE 171 US: TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 181
TABLE 172 US: TISSUE ENGINEERING SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 173 US: BIOLOGICAL SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 174 US: TISSUE ENGINEERING GRAFTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 182
TABLE 175 US: TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2028 (USD MILLION) 182
TABLE 176 US: TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 183
TABLE 177 US: TISSUE ENGINEERING MARKET, BY END USER, 2021–2028 (USD MILLION) 183
10.2.2 CANADA 183
10.2.2.1 Rising investments in R&D to propel market 183
TABLE 178 CANADA: TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 184
TABLE 179 CANADA: TISSUE ENGINEERING SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 184
TABLE 180 CANADA: BIOLOGICAL SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 185
TABLE 181 CANADA: TISSUE ENGINEERING GRAFTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 185
TABLE 182 CANADA: TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2028 (USD MILLION) 186
TABLE 183 CANADA: TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 186
TABLE 184 CANADA: TISSUE ENGINEERING MARKET, BY END USER, 2021–2028 (USD MILLION) 187
10.2.3 RECESSION IMPACT ON NORTH AMERICAN TISSUE ENGINEERING MARKET 187
10.3 EUROPE 188
TABLE 185 EUROPE: TISSUE ENGINEERING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 188
TABLE 186 EUROPE: TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 188
TABLE 187 EUROPE: TISSUE ENGINEERING SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 189
TABLE 188 EUROPE: BIOLOGICAL SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 189
TABLE 189 EUROPE: TISSUE ENGINEERING GRAFTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 190
TABLE 190 EUROPE: TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2028 (USD MILLION) 190
TABLE 191 EUROPE: TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 191
TABLE 192 EUROPE: TISSUE ENGINEERING MARKET, BY END USER, 2021–2028 (USD MILLION) 191
10.3.1 UK 191
10.3.1.1 Increasing adoption of advanced technologies to drive market 191
TABLE 193 UK: TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 192
TABLE 194 UK: TISSUE ENGINEERING SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 193
TABLE 195 UK: BIOLOGICAL SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 193
TABLE 196 UK: TISSUE ENGINEERING GRAFTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 194
TABLE 197 UK: TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2028 (USD MILLION) 194
TABLE 198 UK: TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 195
TABLE 199 UK: TISSUE ENGINEERING MARKET, BY END USER, 2021–2028 (USD MILLION) 195
10.3.2 GERMANY 195
10.3.2.1 Rising strategic alliances between industry leaders to support market growth 195
TABLE 200 GERMANY: TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 196
TABLE 201 GERMANY: TISSUE ENGINEERING SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 196
TABLE 202 GERMANY: BIOLOGICAL SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 197
TABLE 203 GERMANY: TISSUE ENGINEERING GRAFTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 197
TABLE 204 GERMANY: TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2028 (USD MILLION) 198
TABLE 205 GERMANY: TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 198
TABLE 206 GERMANY: TISSUE ENGINEERING MARKET, BY END USER, 2021–2028 (USD MILLION) 199
10.3.3 FRANCE 199
10.3.3.1 Growing focus on R&D activities related to stem cell products to drive market 199
TABLE 207 FRANCE: TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 200
TABLE 208 FRANCE: TISSUE ENGINEERING SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 200
TABLE 209 FRANCE: BIOLOGICAL SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 200
TABLE 210 FRANCE: TISSUE ENGINEERING GRAFTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 201
TABLE 211 FRANCE: TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2028 (USD MILLION) 201
TABLE 212 FRANCE: TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 202
TABLE 213 FRANCE: TISSUE ENGINEERING MARKET, BY END USER, 2021–2028 (USD MILLION) 202
10.3.4 ITALY 202
10.3.4.1 Growing focus on cell biology research to propel market 202
TABLE 214 ITALY: TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 203
TABLE 215 ITALY: TISSUE ENGINEERING SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 203
TABLE 216 ITALY: BIOLOGICAL SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 204
TABLE 217 ITALY: TISSUE ENGINEERING GRAFTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 204
TABLE 218 ITALY: TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2028 (USD MILLION) 205
TABLE 219 ITALY: TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 205
TABLE 220 ITALY: TISSUE ENGINEERING MARKET, BY END USER, 2021–2028 (USD MILLION) 205
10.3.5 SPAIN 206
10.3.5.1 Growing R&D activities and investments across biopharmaceutical industry to support market growth 206
TABLE 221 SPAIN: TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 206
TABLE 222 SPAIN: TISSUE ENGINEERING SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 207
TABLE 223 SPAIN: BIOLOGICAL SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 207
TABLE 224 SPAIN: TISSUE ENGINEERING GRAFTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 207
TABLE 225 SPAIN: TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2028 (USD MILLION) 208
TABLE 226 SPAIN: TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 208
TABLE 227 SPAIN: TISSUE ENGINEERING MARKET, BY END USER, 2021–2028 (USD MILLION) 208
10.3.6 REST OF EUROPE 209
TABLE 228 REST OF EUROPE: TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 209
TABLE 229 REST OF EUROPE: TISSUE ENGINEERING SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 210
TABLE 230 REST OF EUROPE: BIOLOGICAL SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 210
TABLE 231 REST OF EUROPE: TISSUE ENGINEERING GRAFTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 211
TABLE 232 REST OF EUROPE: TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2028 (USD MILLION) 211
TABLE 233 REST OF EUROPE: TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 212
TABLE 234 REST OF EUROPE: TISSUE ENGINEERING MARKET, BY END USER, 2021–2028 (USD MILLION) 212
10.3.7 RECESSION IMPACT ON EUROPEAN TISSUE ENGINEERING MARKET 213
10.4 ASIA PACIFIC 213
FIGURE 28 ASIA PACIFIC: TISSUE ENGINEERING MARKET SNAPSHOT 215
TABLE 235 ASIA PACIFIC: TISSUE ENGINEERING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 216
TABLE 236 ASIA PACIFIC: TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 216
TABLE 237 ASIA PACIFIC: TISSUE ENGINEERING SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 217
TABLE 238 ASIA PACIFIC: BIOLOGICAL SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 217
TABLE 239 ASIA PACIFIC: TISSUE ENGINEERING GRAFTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 218
TABLE 240 ASIA PACIFIC: TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2028 (USD MILLION) 218
TABLE 241 ASIA PACIFIC: TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 219
TABLE 242 ASIA PACIFIC: TISSUE ENGINEERING MARKET, BY END USER, 2021–2028 (USD MILLION) 219
10.4.1 JAPAN 220
10.4.1.1 Growing support by regulatory bodies for development of advanced solutions to drive market 220
TABLE 243 JAPAN: TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 220
TABLE 244 JAPAN: TISSUE ENGINEERING SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 221
TABLE 245 JAPAN: BIOLOGICAL SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 221
TABLE 246 JAPAN: TISSUE ENGINEERING GRAFTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 221
TABLE 247 JAPAN: TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2028 (USD MILLION) 222
TABLE 248 JAPAN: TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 222
TABLE 249 JAPAN: TISSUE ENGINEERING MARKET, BY END USER, 2021–2028 (USD MILLION) 222
10.4.2 CHINA 223
10.4.2.1 Increasing demand for innovative treatment solutions to propel market 223
TABLE 250 CHINA: TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 223
TABLE 251 CHINA: TISSUE ENGINEERING SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 224
TABLE 252 CHINA: BIOLOGICAL SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 224
TABLE 253 CHINA: TISSUE ENGINEERING GRAFTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 225
TABLE 254 CHINA: TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2028 (USD MILLION) 225
TABLE 255 CHINA: TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 225
TABLE 256 CHINA: TISSUE ENGINEERING MARKET, BY END USER, 2021–2028 (USD MILLION) 226
10.4.3 INDIA 226
10.4.3.1 Growing demand for advanced treatment solutions to support market growth 226
TABLE 257 INDIA: TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 227
TABLE 258 INDIA: TISSUE ENGINEERING SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 227
TABLE 259 INDIA: BIOLOGICAL SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 227
TABLE 260 INDIA: TISSUE ENGINEERING GRAFTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 228
TABLE 261 INDIA: TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2028 (USD MILLION) 228
TABLE 262 INDIA: TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 228
TABLE 263 INDIA: TISSUE ENGINEERING MARKET, BY END USER, 2021–2028 (USD MILLION) 229
10.4.4 SOUTH KOREA 229
10.4.4.1 Strong government regulations related to regenerative medicine to drive market 229
TABLE 264 SOUTH KOREA: TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 230
TABLE 265 SOUTH KOREA: TISSUE ENGINEERING SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 230
TABLE 266 SOUTH KOREA: BIOLOGICAL SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 230
TABLE 267 SOUTH KOREA: TISSUE ENGINEERING GRAFTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 231
TABLE 268 SOUTH KOREA: TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2028 (USD MILLION) 231
TABLE 269 SOUTH KOREA: TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 232
TABLE 270 SOUTH KOREA: TISSUE ENGINEERING MARKET, BY END USER, 2021–2028 (USD MILLION) 232
10.4.5 REST OF ASIA PACIFIC 232
TABLE 271 REST OF ASIA PACIFIC: TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 233
TABLE 272 REST OF ASIA PACIFIC: TISSUE ENGINEERING SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 234
TABLE 273 REST OF ASIA PACIFIC: BIOLOGICAL SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 234
TABLE 274 REST OF ASIA PACIFIC: TISSUE ENGINEERING GRAFTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 235
TABLE 275 REST OF ASIA PACIFIC: TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2028 (USD MILLION) 235
TABLE 276 REST OF ASIA PACIFIC: TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 236
TABLE 277 REST OF ASIA PACIFIC: TISSUE ENGINEERING MARKET, BY END USER, 2021–2028 (USD MILLION) 236
10.4.6 RECESSION IMPACT ON ASIA PACIFIC TISSUE ENGINEERING MARKET 236
10.5 LATIN AMERICA 237
TABLE 278 LATIN AMERICA: TISSUE ENGINEERING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 237
TABLE 279 LATIN AMERICA: TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 238
TABLE 280 LATIN AMERICA: TISSUE ENGINEERING SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 238
TABLE 281 LATIN AMERICA: BIOLOGICAL SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 239
TABLE 282 LATIN AMERICA: TISSUE ENGINEERING GRAFTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 239
TABLE 283 LATIN AMERICA: TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2028 (USD MILLION) 240
TABLE 284 LATIN AMERICA: TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 240
TABLE 285 LATIN AMERICA: TISSUE ENGINEERING MARKET, BY END USER, 2021–2028 (USD MILLION) 241
10.5.1 BRAZIL 241
10.5.1.1 Increase in pharmaceutical R&D to support market growth 241
TABLE 286 BRAZIL: TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 242
TABLE 287 BRAZIL: TISSUE ENGINEERING SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 242
TABLE 288 BRAZIL: BIOLOGICAL SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 243
TABLE 289 BRAZIL: TISSUE ENGINEERING GRAFTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 243
TABLE 290 BRAZIL: TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2028 (USD MILLION) 244
TABLE 291 BRAZIL: TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 244
TABLE 292 BRAZIL: TISSUE ENGINEERING MARKET, BY END USER, 2021–2028 (USD MILLION) 244
10.5.2 MEXICO 245
10.5.2.1 Increased demand for regenerative therapies to propel market 245
TABLE 293 MEXICO: TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 245
TABLE 294 MEXICO: TISSUE ENGINEERING SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 245
TABLE 295 MEXICO: BIOLOGICAL SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 246
TABLE 296 MEXICO: TISSUE ENGINEERING GRAFTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 246
TABLE 297 MEXICO: TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2028 (USD MILLION) 246
TABLE 298 MEXICO: TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 247
TABLE 299 MEXICO: TISSUE ENGINEERING MARKET, BY END USER, 2021–2028 (USD MILLION) 247
10.5.3 REST OF LATIN AMERICA 248
TABLE 300 REST OF LATIN AMERICA: TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 248
TABLE 301 REST OF LATIN AMERICA: TISSUE ENGINEERING SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 248
TABLE 302 REST OF LATIN AMERICA: BIOLOGICAL SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 249
TABLE 303 REST OF LATIN AMERICA: TISSUE ENGINEERING GRAFTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 249
TABLE 304 REST OF LATIN AMERICA: TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2028 (USD MILLION) 250
TABLE 305 REST OF LATIN AMERICA: TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 250
TABLE 306 REST OF LATIN AMERICA: TISSUE ENGINEERING MARKET, BY END USER, 2021–2028 (USD MILLION) 251
10.5.4 RECESSION IMPACT ON LATIN AMERICAN TISSUE ENGINEERING MARKET 251
10.6 MIDDLE EAST & AFRICA 252
TABLE 307 MIDDLE EAST & AFRICA: TISSUE ENGINEERING MARKET, BY REGION, 2021–2028 (USD MILLION) 252
TABLE 308 MIDDLE EAST & AFRICA: TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 253
TABLE 309 MIDDLE EAST & AFRICA: TISSUE ENGINEERING SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 253
TABLE 310 MIDDLE EAST & AFRICA: BIOLOGICAL SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 254
TABLE 311 MIDDLE EAST & AFRICA: TISSUE ENGINEERING GRAFTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 254
TABLE 312 MIDDLE EAST & AFRICA: TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2028 (USD MILLION) 255
TABLE 313 MIDDLE EAST & AFRICA: TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 255
TABLE 314 MIDDLE EAST & AFRICA: TISSUE ENGINEERING MARKET, BY END USER, 2021–2028 (USD MILLION) 256
10.6.1 MIDDLE EAST 256
10.6.1.1 Increased government investments in biomedical research to drive market 256
TABLE 315 MIDDLE EAST: TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 256
TABLE 316 MIDDLE EAST: TISSUE ENGINEERING SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 257
TABLE 317 MIDDLE EAST: BIOLOGICAL SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 257
TABLE 318 MIDDLE EAST: TISSUE ENGINEERING GRAFTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 258
TABLE 319 MIDDLE EAST: TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2028 (USD MILLION) 258
TABLE 320 MIDDLE EAST: TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 259
TABLE 321 MIDDLE EAST: TISSUE ENGINEERING MARKET, BY END USER, 2021–2028 (USD MILLION) 259
10.6.2 AFRICA 260
10.6.2.1 Need for advanced regenerative medicine to support market growth 260
TABLE 322 AFRICA: TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 260
TABLE 323 AFRICA: TISSUE ENGINEERING SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 261
TABLE 324 AFRICA: BIOLOGICAL SCAFFOLDS MARKET, BY TYPE, 2021–2028 (USD MILLION) 261
TABLE 325 AFRICA: TISSUE ENGINEERING GRAFTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 262
TABLE 326 AFRICA: TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2028 (USD MILLION) 262
TABLE 327 AFRICA: TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 263
TABLE 328 AFRICA: TISSUE ENGINEERING MARKET, BY END USER, 2021–2028 (USD MILLION) 263
10.6.3 RECESSION IMPACT ON MIDDLE EAST & AFRICAN TISSUE ENGINEERING MARKET 264
11 COMPETITIVE LANDSCAPE 265
11.1 OVERVIEW 265
11.2 STRATEGIES ADOPTED BY KEY PLAYERS 266
FIGURE 29 TISSUE ENGINEERING MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 266
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 267
FIGURE 30 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN TISSUE ENGINEERING MARKET, 2018–2022 (USD MILLION) 267
11.4 MARKET SHARE ANALYSIS 267
FIGURE 31 TISSUE ENGINEERING MARKET SHARE, BY KEY PLAYER, 2022 268
TABLE 329 TISSUE ENGINEERING MARKET: DEGREE OF COMPETITION 268
11.5 COMPANY EVALUATION MATRIX 269
11.5.1 STARS 270
11.5.2 EMERGING LEADERS 270
11.5.3 PERVASIVE PLAYERS 270
11.5.4 PARTICIPANTS 270
FIGURE 32 TISSUE ENGINEERING MARKET: COMPANY EVALUATION MATRIX, 2022 271
11.5.5 COMPANY FOOTPRINT 272
TABLE 330 OVERALL COMPANY FOOTPRINT 272
TABLE 331 PRODUCT FOOTPRINT 273
TABLE 332 REGIONAL FOOTPRINT 274
11.6 STARTUP/SME EVALUATION MATRIX 275
11.6.1 PROGRESSIVE COMPANIES 275
11.6.2 RESPONSIVE COMPANIES 275
11.6.3 DYNAMIC COMPANIES 275
11.6.4 STARTING BLOCKS 275
FIGURE 33 TISSUE ENGINEERING MARKET: STARTUP/SME EVALUATION MATRIX (2022) 276
11.7 COMPETITIVE BENCHMARKING 277
TABLE 333 TISSUE ENGINEERING MARKET: DETAILED LIST OF KEY STARTUPS/SMES 277
TABLE 334 TISSUE ENGINEERING MARKET: PRODUCT & REGIONAL FOOTPRINT OF KEY STARTUPS/SMES 278
11.8 COMPETITIVE SCENARIO AND TRENDS 278
TABLE 335 TISSUE ENGINEERING MARKET: KEY PRODUCT LAUNCHES, JANUARY 2020−NOVEMBER 2023 278
TABLE 336 TISSUE ENGINEERING MARKET: KEY DEALS, JANUARY 2020− NOVEMBER 2023 279
TABLE 337 TISSUE ENGINEERING MARKET: OTHER DEVELOPMENTS, JANUARY 2020−NOVEMBER 2023 280
12 COMPANY PROFILES 281
12.1 MAJOR PLAYERS 281
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
12.1.1 ORGANOGENESIS INC. 281
TABLE 338 ORGANOGENESIS INC.: BUSINESS OVERVIEW 281
FIGURE 34 ORGANOGENESIS INC.: COMPANY SNAPSHOT (2022) 282
12.1.2 INTEGRA LIFESCIENCES 285
TABLE 339 INTEGRA LIFESCIENCES: BUSINESS OVERVIEW 285
FIGURE 35 INTEGRA LIFESCIENCES: COMPANY SNAPSHOT (2022) 286
12.1.3 ABBVIE INC. 290
TABLE 340 ABBVIE INC.: BUSINESS OVERVIEW 290
FIGURE 36 ABBVIE INC.: COMPANY SNAPSHOT (2022) 291
12.1.4 MIMEDX GROUP, INC. 294
TABLE 341 MIMEDX GROUP, INC.: BUSINESS OVERVIEW 294
FIGURE 37 MIMEDX GROUP, INC.: COMPANY SNAPSHOT (2022) 294
12.1.5 JOHNSON & JOHNSON SERVICES, INC. 298
TABLE 342 JOHNSON & JOHNSON SERVICES, INC.: BUSINESS OVERVIEW 298
FIGURE 38 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2022) 299
12.1.6 SMITH & NEPHEW PLC 301
TABLE 343 SMITH & NEPHEW PLC: BUSINESS OVERVIEW 301
FIGURE 39 SMITH & NEPHEW PLC: COMPANY SNAPSHOT (2022) 302
12.1.7 BAXTER 305
TABLE 344 BAXTER: BUSINESS OVERVIEW 305
FIGURE 40 BAXTER: COMPANY SNAPSHOT (2022) 306
12.1.8 BD 308
TABLE 345 BD: BUSINESS OVERVIEW 308
FIGURE 41 BD: COMPANY SNAPSHOT (2023) 309
12.1.9 B. BRAUN SE 311
TABLE 346 B. BRAUN SE: BUSINESS OVERVIEW 311
FIGURE 42 B. BRAUN SE: COMPANY SNAPSHOT (2022) 312
12.1.10 TEIJIN LIMITED 314
TABLE 347 TEIJIN LIMITED: BUSINESS OVERVIEW 314
FIGURE 43 TEIJIN LIMITED: COMPANY SNAPSHOT (2022) 315
12.1.11 INSTITUT STRAUMANN AG 318
TABLE 348 INSTITUT STRAUMANN AG: BUSINESS OVERVIEW 318
FIGURE 44 INSTITUT STRAUMANN AG: COMPANY SNAPSHOT (2022) 319
12.1.12 MEDTRONIC 321
TABLE 349 MEDTRONIC: BUSINESS OVERVIEW 321
FIGURE 45 MEDTRONIC: COMPANY SNAPSHOT (2023) 322
12.1.13 NUVASIVE, INC. 324
TABLE 350 NUVASIVE, INC.: BUSINESS OVERVIEW 324
FIGURE 46 NUVASIVE, INC.: COMPANY SNAPSHOT (2022) 325
12.1.14 STRYKER 328
TABLE 351 STRYKER: BUSINESS OVERVIEW 328
FIGURE 47 STRYKER: COMPANY SNAPSHOT (2022) 329
12.1.15 TERUMO CORPORATION 333
TABLE 352 TERUMO CORPORATION: BUSINESS OVERVIEW 333
FIGURE 48 TERUMO CORPORATION: COMPANY SNAPSHOT (2022) 334
12.1.16 W. L. GORE & ASSOCIATES, INC. 335
TABLE 353 W. L. GORE & ASSOCIATES, INC.: BUSINESS OVERVIEW 335
12.1.17 ZIMMER BIOMET 337
TABLE 354 ZIMMER BIOMET: BUSINESS OVERVIEW 337
FIGURE 49 ZIMMER BIOMET: COMPANY SNAPSHOT (2022) 338
12.2 OTHER PLAYERS 341
12.2.1 BIOTISSUE 341
TABLE 355 BIOTISSUE: COMPANY OVERVIEW 341
12.2.2 COLLPLANT BIOTECHNOLOGIES LTD. 342
TABLE 356 COLLPLANT BIOTECHNOLOGIES LTD.: COMPANY OVERVIEW 342
12.2.3 SUMITOMO PHARMA CO., LTD. 343
TABLE 357 SUMITOMO PHARMA CO., LTD.: COMPANY OVERVIEW 343
12.2.4 MATRICEL GMBH 344
TABLE 358 MATRICEL GMBH: COMPANY OVERVIEW 344
12.2.5 MALLINCKRODT 345
TABLE 359 MALLINCKRODT: COMPANY OVERVIEW 345
12.2.6 REGROW BIOSCIENCES PVT. LTD. 346
TABLE 360 REGROW BIOSCIENCES PVT. LTD.: COMPANY OVERVIEW 346
12.2.7 VERICEL CORPORATION 347
TABLE 361 VERICEL CORPORATION: COMPANY OVERVIEW 347
12.2.8 TECNOSS S.R.L. 348
TABLE 362 TECNOSS S.R.L.: COMPANY OVERVIEW 348
12.2.9 TEGOSCIENCE 349
TABLE 363 TEGOSCIENCE: COMPANY OVERVIEW 349
12.2.10 TISSUE REGENIX 350
TABLE 364 TISSUE REGENIX: COMPANY OVERVIEW 350
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
13 APPENDIX 351
13.1 DISCUSSION GUIDE 351
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 355
13.3 CUSTOMIZATION OPTIONS 357
13.4 RELATED REPORTS 357
13.5 AUTHOR DETAILS 358